WallStreetZenWallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Vertex Pharmaceuticals earnings were $4.4B for the trailing 12 months ending Jun 30, 2026, with 22.7% growth year over year. The latest VRTX earnings report on Jun 30, 2026 announced Q2 2026 earnings of $1.1B, up 6.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VRTX reported annual earnings of $4.0B, with -838.1% growth.

VRTX past earnings growth

How has VRTX's earnings growth performed historically?

Company
22.73%
Industry
17.19%
Market
93.08%
VRTX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
VRTX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
VRTX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

VRTX earnings history

Current Revenue
$12.6B
Current Earnings
$4.4B
Current Profit Margin
35%

VRTX Return on Equity

Current Company
23.3%
Current Industry
-13.6%
Current Market
33%
VRTX's Return on Equity (23.3%)... subscribe to Premium to read more.
High Return on Equity Performance

VRTX Return on Assets

Current Company
16.9%
Current Industry
-10.2%
VRTX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when VRTX announces earnings.

VRTX Return on Capital Employed

Current Company
22.49%
Current Industry
-6.7%
VRTX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VRTX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
VRTX$5.50B$4.41B+17.68%$17.33
REGN$5.75B$4.33B-6.56%$41.94
NVO$27.06B$17.91B+21.21%$4.04
ARGX$2.03B$1.95B+26.02%$31.53
MRNA-$2.85B-$3.15BN/A-$7.99
View Top Biotech Stocks

Vertex Pharmaceuticals Earnings Reports & History FAQ

What were Vertex Pharmaceuticals's earnings last quarter?

On VRTX's earnings call on Aug 3, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) reported Q2 2026 earnings per share (EPS) of $4.34, up 7.96% year over year. Total VRTX earnings for the quarter were $1.10 billion. In the same quarter last year, Vertex Pharmaceuticals's earnings per share (EPS) was $4.02.

If you're new to stock investing, here's how to buy Vertex Pharmaceuticals stock.

Is Vertex Pharmaceuticals profitable or losing money?

As of the last Vertex Pharmaceuticals earnings report, Vertex Pharmaceuticals is currently profitable. Vertex Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $4.41 billion, a 21.1% increase year over year.

What was VRTX's earnings growth in the past year?

As of Vertex Pharmaceuticals's earnings date in Aug 3, 2026, Vertex Pharmaceuticals's earnings has grown 22.73% year over year. This is 5.54 percentage points higher than the US Biotechnology industry earnings growth rate of 17.19%. VRTX earnings in the past year totalled $4.41 billion.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.